Tags

Type your tag names separated by a space and hit enter

Statin Toxicity.
Circ Res. 2019 01 18; 124(2):328-350.CircR

Abstract

There is now overwhelming evidence to support lowering LDL-c (low-density lipoprotein cholesterol) to reduce cardiovascular morbidity and mortality. Statins are a class of drugs frequently prescribed to lower cholesterol. However, in spite of their wide-spread use, discontinuation and nonadherence remains a major gap in both the primary and secondary prevention of atherosclerotic cardiovascular disease. The major reason for statin discontinuation is because of the development of statin-associated muscle symptoms, but a range of other statin-induced side effects also exist. Although the mechanisms behind these side effects have not been fully elucidated, there is an urgent need to identify those at increased risk of developing side effects as well as provide alternative treatment strategies. In this article, we review the mechanisms and clinical importance of statin toxicity and focus on the evaluation and management of statin-associated muscle symptoms.

Authors+Show Affiliations

From the School of Public Health, Curtin University, Perth, Western Australia, Australia (N.C.W.). School of Medicine, University of Western Australia, Perth, Australia (N.C.W., G.F.W.).School of Medicine, University of Western Australia, Perth, Australia (N.C.W., G.F.W.). Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, Western Australia, Australia (G.F.W.).Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora (R.H.E.).

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30653440

Citation

Ward, Natalie C., et al. "Statin Toxicity." Circulation Research, vol. 124, no. 2, 2019, pp. 328-350.
Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019;124(2):328-350.
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019). Statin Toxicity. Circulation Research, 124(2), 328-350. https://doi.org/10.1161/CIRCRESAHA.118.312782
Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019 01 18;124(2):328-350. PubMed PMID: 30653440.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statin Toxicity. AU - Ward,Natalie C, AU - Watts,Gerald F, AU - Eckel,Robert H, PY - 2019/1/18/entrez PY - 2019/1/18/pubmed PY - 2019/11/19/medline KW - atherosclerosis KW - cholesterol KW - hyperlipidemia KW - risk KW - statin SP - 328 EP - 350 JF - Circulation research JO - Circ. Res. VL - 124 IS - 2 N2 - There is now overwhelming evidence to support lowering LDL-c (low-density lipoprotein cholesterol) to reduce cardiovascular morbidity and mortality. Statins are a class of drugs frequently prescribed to lower cholesterol. However, in spite of their wide-spread use, discontinuation and nonadherence remains a major gap in both the primary and secondary prevention of atherosclerotic cardiovascular disease. The major reason for statin discontinuation is because of the development of statin-associated muscle symptoms, but a range of other statin-induced side effects also exist. Although the mechanisms behind these side effects have not been fully elucidated, there is an urgent need to identify those at increased risk of developing side effects as well as provide alternative treatment strategies. In this article, we review the mechanisms and clinical importance of statin toxicity and focus on the evaluation and management of statin-associated muscle symptoms. SN - 1524-4571 UR - https://www.unboundmedicine.com/medline/citation/30653440/Statin_Toxicity_ L2 - http://www.ahajournals.org/doi/full/10.1161/CIRCRESAHA.118.312782?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -